期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

阿托伐他汀与氯吡格雷对急性冠状动脉综合征患者血小板聚集率的影响 被引量：2

在线阅读 下载PDF
导出
摘要 目的探讨阿托伐他汀和氯吡格雷对急性冠状动脉综合征(ACS)患者血小板聚集率的影响。方法选择66例ACS患者作为ACS组,25例健康志愿者作为对照组。ACS组患者在常规药物治疗基础上均予阿司匹林(100 mg/d)、氯吡格雷(75mg/d)和阿托伐他汀(20mg/d)治疗。对照组志愿者均予阿司匹林肠溶片、氯吡格雷和阿托伐他汀口服,药品来源、剂量与ACS组相同。采用流式细胞仪测定上述受试者的血小板聚集率。结果对照组志愿者分别采用双联抗血小板联合阿托伐他汀治疗以及双联抗血小板治疗,血小板聚集率分别为(44.27±16.37)%、(47.61±16.67)%,二者差异无统计学意义(P>0.05)。ACS组患者采用上述2种方法治疗,血小板聚集率分别为(47.70±15.07)%、(47.03±15.45)%,二者差异无统计学意义(P>0.05)。结论氯吡格雷与阿托伐他汀联合治疗不影响氯吡格雷的抗血小板作用,二者无相互作用。
作者 王燕慧 张灏 魏宏顺 孟晓冬 李琦 方岩 王静 王淑宏 裴一璇
机构地区 甘肃省第二人民医院重症医学科 甘肃省第二人民医院心内科 甘肃省第二人民医院急诊科
出处 《国际检验医学杂志》 CAS 2013年第21期2910-2912,共3页 International Journal of Laboratory Medicine
基金 甘肃省卫生行业科研计划项目(GSWST2010-21)
关键词 急性冠状动脉综合征 阿托伐他汀 氯吡格雷 血小板聚集率
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献14

  • 1Cavusoglu Ev ChengJ,Bhatt Rv ot al. Clopidogrel in the manage?ment of ischemic heart disease] J]. Heart Dis. 2003.5 (2): 144- 152.
  • 2王燕慧,张灏.他汀类药物与氯吡格雷相互作用争议的现状[J].国际心血管病杂志,2011,38(2):104-107. 被引量：20
  • 3Vlachojannis GJ ? Dimitropoulos G.Alexopoulos D. Clopidogrel re?sistance: current aspects and future directions[J]. HellenicJ Car?diol , 2011. 52(3): 236-245.
  • 4Bozbeyoglu E. Satilmis S. Aksu H. et al. Impact of clopidogrel re?sistance on ST-segment resolution and no-reflow in acute myocar?dial infarction with ST-elevation patients treated with a primary percutaneous coronary intervention[J]. Coron Artery Dis. 2012. 23(S) :523-527.
  • 5Lau WC. Waskell LA. Watkins PB. Atorvastatin reduces the abili?ty of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction[J]. Circulation. 2003 .107 (1) : 32-37.
  • 6BrophyJ Mv Babapulle MN ? Costa V. et al. A pharmacoepidemiolo?gy study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention[J]. Am HeartJ. 2006. 152(2) :263-269.
  • 7Serebruany VL, Steinhubl SR. Hennekens CH. Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research ques?tion formulated but not yet adequately tested[J]. Circulation. 2003.107(12):1568-1569.
  • 8SawJ ? Brennan DM.Steinhubl SR.et al. Lack of evidence of a clo?pidogrel-statin interaction in the CHARISMA trial[J].J Am Coli Cardiol.2007 .50(4) :291-295.
  • 9SawJ .Steinhubl SR.Berger PB.et al. Lack of adverse clopidogrel?atorvastatin clinical interaction from secondary analysis of a ran?domized. placebo-controlled clopidogrel trial[J]. Circulation. 2003 ? 10S(S) :921-924.
  • 10Wienbergen H. Gitt AK. Schiele R. et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other stat in therapies[J]. AmJ Cardio\,2003,92(3) :285-288.

二级参考文献26

  • 1Porto I, Van Gaal W, Banning A. Impact of the elevation of biochemical markers of myocardial damage on long term mortality after percutaneous coronary intervention: results of theCK MBand PCI study[J]. Eur Heart J, 2005,26(20): 2206-2207.
  • 2Briguori C, Visconti G, Focaccio A, et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction[J]. J Am Coll Cardiol, 2009,54 (23) : 2157-2163.
  • 3Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early pereutaneous coronary intervention: results of the ARMYDA ACS randomized trial [J]. J Am Coll Cardiol, 2007,49(12) :1272- 1278.
  • 4Di Sciascio G, Patti G, Pasceri V, et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention : results of the ARMYDA RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial [J]. J AmCollCardiol, 2009,54(6):558 -565.
  • 5Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives[J]. J Am Coll Cardiol, 2007,49(14) :1505 -1516.
  • 6Marian AJ. Cytochrome p-450 polymorphisms and response to clopidogrel[J]. Curr Atheroscler Rep, 2009,11(3):157-160.
  • 7Neubauer H, Gtinesdogan B, Hanefeld C, et al. Lipophilic statins interfere with the inhibitory effects of elopidogrel on platelet function-a flow cytometry study[J]. Eur Heart J, 2003,24(19) : 1744-1749.
  • 8Brophy JM, Babapulle MN, Costa V, et al. A pharmacoe pidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention[J]. Am Heart J, 2006,152(2) :263 -269.
  • 9Saw J, Brennan DM, Steinhubl SR,et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial[J]. J Am Coll Cardiol, 2007,50(4):291-295.
  • 10Lim MJ, Spencer FA, Gore JM, et al. Impact of combined pharmacologic treatment with elopidogrel and a statin on outcomes of patients with non-ST segment elevation acute coronary syndromes: perspectives from a large multinational registry[J]. Eur Heart J, 2005, 26(11):1063-1069.

共引文献19

同被引文献12

引证文献2

二级引证文献11

国际检验医学杂志
2013年 第21期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
关于我们 | 版权声明 | 联系我们 | 帮助中心| 意见反馈
主办单位：上海市教育委员会
技术支持：重庆维普资讯有限公司
渝公网安备 50019002500403号
使用帮助 返回顶部